MYELOMA
Clinical trials for MYELOMA explained in plain language.
Never miss a new study
Get alerted when new MYELOMA trials appear
Sign up with your email to follow new studies for MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New 5-Drug cocktail aims to tackle High-Risk myeloma
Disease control Not yet recruitingThis study tests a new five-drug combination for people newly diagnosed with a high-risk form of multiple myeloma. The drugs include etentamig, isatuximab, bortezomib, lenalidomide, and dexamethasone. The trial will enroll 220 participants and first check safety, then see if the …
Matched conditions: MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Engineered immune cells take aim at CD70-Positive cancers in new trial
Disease control Not yet recruitingThis early-phase trial tests a new type of immunotherapy called CD70 CAR T cells in people with lymphoma, myeloma, and certain solid tumors (like kidney cancer and sarcomas) that have come back or not responded to standard treatments. The immune cells are modified in the lab to r…
Matched conditions: MYELOMA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
French study to probe alternative medicine use in blood cancer patients
Knowledge-focused Not yet recruitingThis study looks at how people with blood cancers (like leukemia, lymphoma, or myeloma) in France use complementary and alternative medicines (CAM), such as acupuncture or herbal remedies. Researchers will survey 85 patients and interview some to understand why they use these the…
Matched conditions: MYELOMA
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Real-World data sought on myeloma drug combo
Knowledge-focused Not yet recruitingThis study will review medical records of 300 UK patients with newly diagnosed multiple myeloma who cannot have a stem cell transplant and are treated with a three-drug combination (daratumumab, lenalidomide, and dexamethasone). The goal is to see how well this therapy works in e…
Matched conditions: MYELOMA
Sponsor: The Royal Wolverhampton Hospitals NHS Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC